Literature DB >> 28031194

Azithromycin-Ciprofloxacin-Impregnated Urinary Catheters Avert Bacterial Colonization, Biofilm Formation, and Inflammation in a Murine Model of Foreign-Body-Associated Urinary Tract Infections Caused by Pseudomonas aeruginosa.

Hina Saini1, Anitha Vadekeetil1, Sanjay Chhibber1, Kusum Harjai2.   

Abstract

Pseudomonas aeruginosa is a multifaceted pathogen causing a variety of biofilm-mediated infections, including catheter-associated urinary tract infections (CAUTIs). The high prevalence of CAUTIs in hospitals, their clinical manifestations, such as urethritis, cystitis, pyelonephritis, meningitis, urosepsis, and death, and the associated economic challenges underscore the need for management of these infections. Biomaterial modification of urinary catheters with two drugs seems an interesting approach to combat CAUTIs by inhibiting biofilm. Previously, we demonstrated the in vitro efficacy of urinary catheters impregnated with azithromycin (AZM) and ciprofloxacin (CIP) against P. aeruginosa Here, we report how these coated catheters impact the course of CAUTI induced by P. aeruginosa in a murine model. CAUTI was established in female LACA mice with uncoated or AZM-CIP-coated silicone implants in the bladder, followed by transurethral inoculation of 108 CFU/ml of biofilm cells of P. aeruginosa PAO1. AZM-CIP-coated implants (i) prevented biofilm formation on the implant's surface (P ≤ 0.01), (ii) restricted bacterial colonization in the bladder and kidney (P < 0.0001), (iii) averted bacteriuria (P < 0.0001), and (iv) exhibited no major histopathological changes for 28 days in comparison to uncoated implants, which showed persistent CAUTI. Antibiotic implants also overcame implant-mediated inflammation, as characterized by trivial levels of inflammatory markers such as malondialdehyde (P < 0.001), myeloperoxidase (P < 0.05), reactive oxygen species (P ≤ 0.001), and reactive nitrogen intermediates (P < 0.01) in comparison to those in uncoated implants. Further, AZM-CIP-coated implants showed immunomodulation by manipulating the release of inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and IL-10 to the benefit of the host. Overall, the study demonstrates long-term in vivo effectiveness of AZM-CIP-impregnated catheters, which may possibly be a key to success in preventing CAUTIs.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  quorum sensing; urinary tract infection

Mesh:

Substances:

Year:  2017        PMID: 28031194      PMCID: PMC5328564          DOI: 10.1128/AAC.01906-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Biomaterial modification of urinary catheters with antimicrobials to give long-term broadspectrum antibiofilm activity.

Authors:  Leanne E Fisher; Andrew L Hook; Waheed Ashraf; Anfal Yousef; David A Barrett; David J Scurr; Xinyong Chen; Emily F Smith; Michael Fay; Christopher D J Parmenter; Richard Parkinson; Roger Bayston
Journal:  J Control Release       Date:  2015-01-30       Impact factor: 9.776

Review 2.  Catheter-associated urinary tract infections: new aspects of novel urinary catheters.

Authors:  U-Syn Ha; Yong-Hyun Cho
Journal:  Int J Antimicrob Agents       Date:  2006-10-12       Impact factor: 5.283

3.  Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains.

Authors:  W J Hopkins; A Gendron-Fitzpatrick; E Balish; D T Uehling
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Macrophage inflammatory protein-2 is required for neutrophil passage across the epithelial barrier of the infected urinary tract.

Authors:  L Hang; M Haraoka; W W Agace; H Leffler; M Burdick; R Strieter; C Svanborg
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

5.  Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial.

Authors:  Rabih O Darouiche; John I Thornby; Colleen Cerra-Stewart; William H Donovan; Richard A Hull
Journal:  Clin Infect Dis       Date:  2005-10-13       Impact factor: 9.079

6.  Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections.

Authors:  Hina Saini; Sanjay Chhibber; Kusum Harjai
Journal:  Int J Antimicrob Agents       Date:  2014-12-16       Impact factor: 5.283

Review 7.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.

Authors:  Nadine Hoffmann; Baoleri Lee; Morten Hentzer; Thomas Bovbjerg Rasmussen; Zhijun Song; Helle Krogh Johansen; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

9.  Contribution of free radicals to Pseudomonas aeruginosa induced acute pyelonephritis.

Authors:  Rahul Mittal; Saroj Sharma; Sanjay Chhibber; Kusum Harjai
Journal:  Microb Pathog       Date:  2008-08-15       Impact factor: 3.738

10.  Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India.

Authors:  Sugata Dasgupta; Soumi Das; Neeraj S Chawan; Avijit Hazra
Journal:  Indian J Crit Care Med       Date:  2015-01
View more
  4 in total

1.  Comparing the Antimicrobial Effect of Silver Ion-Coated Silicone and Gentamicin-Irrigated Silicone Sheets from Breast Implant Material.

Authors:  Fadi Heno; Ziv Azoulay; Boris Khalfin; Hillary A Craddock; Eldad Silberstein; Jacob Moran-Gilad; Hanna Rapaport
Journal:  Aesthetic Plast Surg       Date:  2021-05-26       Impact factor: 2.326

2.  4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.

Authors:  Raj Kc Hansa; M M K Khan; M M Frangie; D F Gilmore; R S Shelton; A V Savenka; A G Basnakian; S L Shuttleworth; M S Smeltzer; M A Alam
Journal:  Eur J Med Chem       Date:  2021-04-04       Impact factor: 7.088

3.  Design and synthesis of 4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivatives as potent growth inhibitors of drug-resistant Staphylococcus aureus.

Authors:  Rawan Alnufaie; Nickolas Alsup; Hansa Raj Kc; Matthew Newman; Jedidiah Whitt; Steven Andrew Chambers; David Gilmore; Mohammad A Alam
Journal:  J Antibiot (Tokyo)       Date:  2020-06-29       Impact factor: 2.649

Review 4.  Repurposing phytochemicals as anti-virulent agents to attenuate quorum sensing-regulated virulence factors and biofilm formation in Pseudomonas aeruginosa.

Authors:  Jatin Chadha; Kusum Harjai; Sanjay Chhibber
Journal:  Microb Biotechnol       Date:  2021-11-29       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.